SEARCH

SEARCH BY CITATION

References

  • 1
    Dent J. Gastro-oesophageal reflux disease. Digestion 1998; 59: 43345.
  • 2
    Dooley CP, Cohen H, Fitzgibbons PL, et al. Prevalence of Helicobacter pylori infection and histological gastritis in asymptomatic persons. N Engl J Med 1989; 321: 15626.
  • 3
    Goldstone AR, Quirke P, Dixon MF. Helicobacter pylori infection and gastric cancer. J Pathol 1996; 179: 12937.DOI: 10.1002/(SICI)1096-9896(199606)179:2<129::AID-PATH504>3.3.CO;2-3
  • 4
    Craanen ME, Dekker W, Blok P, Ferwerda J, Tytgat GN. Intestinal metaplasia and Helicobacter pylori. An endoscopic bioptic study of the gastric antrum. Gut 1992; 33: 1620.
  • 5
    Kuipers E, Uyterlinde A, Pena AS, et al. Long-term sequelae of Helicobacter associated gastritis. Lancet 1995; 345: 15258.
  • 6
    Sipponen P, Kekki M, Siurala M. Atrophic chronic gastritis and intestinal metaplasia in gastric carcinoma. Cancer 1983; 52: 10628.
  • 7
    Corrrea P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19(Suppl. 1): S3743.
  • 8
    Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 112731.
  • 9
    Rokkas T, Filipe I, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991; 32: 11103.
  • 10
    Filipe MI, Munoz M, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994; 57: 3249.
  • 11
    Kuipers E, Lundell L, Klinkenberg-Knol E, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 101822.
  • 12
    Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzaeg P. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997; 41: 7407.
  • 13
    Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther 1998; 12: 73540.DOI: 10.1046/j.1365-2036.1998.00370.x
  • 14
    Eissele R, Brunner G, Sunar B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 70717.
  • 15
    Misiewicz JJ, Tytgat GNJ, Goodwin CS, et al. The Sydney system: a new classification of gastritis. J Gastroenterol Hepatol 1991; 6: 2078.
  • 16
    Dixon MF, Genta RM, Yardley JH, Correa P. Classification and Grading of Gastritis. The updated Sydney system. Am J Surg Pathol 1996; 20: 116181.
  • 17
    Cassaro M, Di Mario F, Leandro G, Genta R, Rugge M. The dark side of the gastric biopsy. Hum Pathol 1999; 30: 7414.
  • 18
    Synnerstad I & Holm L. Omeprazole induces high intraglandular pressure in the rat gastric mucosa. Gastroenterology 1992; 112: 122130.
  • 19
    Stolte M, Bethke B, Seifert E, et al. Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment. Z Gastroenterol 1995; 33: 1469.
  • 20
    Hattlebakk J & Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 1997; 11(2): 36572.
  • 21
    Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. Ann Intern Med 1996; 124: 85967.
  • 22
    Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10(4): 52939.
  • 23
    Lundell L. Long-term treatment of gastro-oesophageal reflux disease with omeprazole. Scand J Gastroenterol 1994; 201: 748.
  • 24
    Festen HP, Schenk E, Tan G, Snel P, Nelis F. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. Am J Gastroenterol 1999; 94(4): 9316.
    Direct Link:
  • 25
    Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenteology 1994; 107(5): 130511.
  • 26
    Plein K, Hotz J, Wurzer H, Fumagalli I, Luhmann R, Schneider A. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2000; 12(4): 42532.
  • 27
    Escourrou J, Deprez P, Saggioro A, Geldof H, Fischer R, Maier C. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Aliment Pharmacol Ther 1999; 13(11): 148191.
  • 28
    Geboes K, Ectors N, Penson P. Le Lansoprazole à long terme reduit l’activité de la gastrite antrale et la présence d’Helicobacter pylori associée à l’ulcère duodenal. Gastroenterol Clin Biol 1995; 19: A190A190(Abstract).
  • 29
    El-Zimaity HMT, Graham DY, Al Assi MT, et al. Interobserver variation in the histological assessment of Helicobacter pylori gastritis. Hum Pathol 1996; 27: 3541.
  • 30
    Guarner J, Herrera-Goepfert R, Mohar A, et al. Interobserver variability in application of the revised Sydney classification for gastritis. Hum Pathol 1999; 30: 14314.
  • 31
    Tosi P, Filipe MI, Luzi P, et al. Gastric intestinal metaplasia type III cases are classified as low-grade dysplasia on the basis of morphometry. J Pathol 1993; 169: 738.
  • 32
    Kekki M, Siurala M, Varis K, Sipponen P, Sistonen P, Nevanlinna HR. Classification, principles and genetics of chronic gastritis. Scand J Gastroenterol 1987; 22(Suppl. 141): 128.
  • 33
    Potet F, Florent C, Benhamou E, et al. Chronic gastritis: prevalence in the French population. Gastroenterol Clin Biol 1993; 17: 1039.
  • 34
    Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term study group. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastoenterology 2000; 118: 6619.
  • 35
    Dekker W, Mulder CJ, Geboes K. Long-term therapy with lansoprazole 30 mg in preventing relapse reflux oesophagitis: clinical and histological evolution at 3 years. Gastroenterology 1999; 119: G063/G063G063/A146(Abstract).
  • 36
    Forbes GM, Warren JR, Glaser ME, Cullen DJ, Marshall BJ, Collins BJ. Long-term follow-up of gastric histology after Helicobacter pylori eradication. J Gastroenterol Hepatol 1996; 11: 6703.
  • 37
    Van der Hulst RWM, Van der Ende A, Dekker FW, et al. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology 1997; 113: 2530.
  • 38
    Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46: 61521.
  • 39
    Hoshi T, Sasano H, Kato K, et al. Cell damage and proliferation in human gastric mucosa infected by Helicobacter pylori—a comparison before and after H. pylori eradication in non-atrophic gastritis. Hum Pathol 1999; 30: 14137.